ArticleCancer control : journal of the Moffitt Cancer Center
Immunotherapy Landscape for Acute Lymphoblastic Leukaemia (ALL) in Malaysia: A Qualitative Study Among Healthcare Professionals From Two National Referral Centres.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionRelapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) carries a poor prognosis in adults. Although immunotherapies have expanded treatment options, access to these life-extending therapies remains a challenge in many resource-constrained healthcare systems. This study explored healthcare professionals' perspectives on the immunotherapy landscape for adult B-ALL in Malaysia's public sector.MethodsA qualitative study was conducted using in-depth, semi-structured interviews with 11 healthcare professionals from two tertiary centres in Malaysia. Interviews were audio-recorded, transcribed verbatim, and analysed using thematic analysis.ResultsSix themes characterised the current implementation landscape. While the clinical benefits of immunotherapy were widely recognised, its use remained largely restricted to salvage or bridging therapy. Financial constraints, fragmented funding mechanisms, administrative burden, infrastructure constraints, limited clinical expertise or experience, and the absence of standardised treatment pathways hindered wider integration into routine care. These collectively contributed to inequitable access and delayed treatment initiation in a setting of a rapidly progressive disease.ConclusionsHealthcare professionals recognise the therapeutic value of immunotherapy for adult B-ALL, but its implementation in Malaysia's public sector remains selective and constrained. Systemic reforms across funding, formulary policy, workforce development, and clinical governance may be needed to close the gap between therapeutic potential and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.